Last Updated: Apr 28, 2016
- Chemoprevention of hereditary colon cancers: time for new strategies.
Ricciardiello Luigi et al. Nature reviews. Gastroenterology & hepatology 2016 Apr - Combined assessment of EGFR-related molecules to predict outcome of 1st-line cetuximab-containing chemotherapy for metastatic colorectal cancer.
Sunakawa Yu, et al. Cancer biology & therapy 2016 4 0 - Two variants on T2DM susceptible gene HHEX are associated with CRC risk in a Chinese population.
Sun Rui, et al. Oncotarget 2016 4 - Allelic loss at PTEN locus leads to progression of colorectal carcinoma among North Indian patients.
Ali Asgar, et al. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2016 4 1-5 - Lack of BRAFV600E mutation in stage I and II of colorectal cancer.
Molaei Mahsa, et al. Gastroenterology and hepatology from bed to bench 2016 0 (2) 94-9 - K-ras gene mutation as an early prognostic marker of colon cancer.
Szpon ?ukasz, et al. Polski przeglad chirurgiczny 2016 1 (1) 15-9 - Sporadic colorectal cancer: Studying ways to an end.
Rosa Isadora, et al. United European gastroenterology journal 2016 4 (2) 288-96 - Type 1 serrated polyposis represents a predominantly female disease with a high prevalence of dysplastic serrated adenomas, without germline mutation in MUTYH, APC, and PTEN genes.
Petronio Marco, et al. United European gastroenterology journal 2016 4 (2) 305-13 - Prognostic and predictive value of extended RAS mutation and mismatch repair status in stage III colorectal cancer.
Sasaki Yusuke, et al. Cancer science 2016 4 - Implementing screening for Lynch syndrome among patients with newly diagnosed colorectal cancer: summary of a public health/clinical collaborative meeting.
Bellcross Cecelia A et al. Genetics in medicine : official journal of the American College of Medical Genetics 2012 Jan 14(1) 152-62 - Prognostic impact of mutation profiling in patients with stage II and III colon cancer.
Shen Yinchen, et al. Scientific reports 2016 0 24310 - Genetic Variants Associated with Colorectal Adenoma Susceptibility.
Abulí Anna, et al. PloS one 2016 0 (4) e0153084 - A genetic network that suppresses genome rearrangements in Saccharomyces cerevisiae and contains defects in cancers.
Putnam Christopher D, et al. Nature communications 2016 0 11256 - The association of clinicopathological features and survival in colorectal cancer patients with kras mutation status.
Akman Tulay, et al. Journal of cancer research and therapeutics 0 0 (1) 96-102 - Prediction of response to combination chemotherapy with irinotecan in Greek patients with metastatic colorectal cancer.
Isaakidou Athina, et al. Journal of cancer research and therapeutics 0 0 (1) 193-7 - Genetic and epigenetic variation in the DNMT3B and MTHFR genes and colorectal adenoma risk.
Ho Vikki, et al. Environmental and molecular mutagenesis 2016 5 (4) 261-8 - Multivitamin, calcium and folic acid supplements and the risk of colorectal cancer in Lynch syndrome.
Chau Rowena, et al. International journal of epidemiology 2016 4 - Lynch syndrome mutation spectrum in New South Wales, Australia, including 55 novel mutations.
Sjursen Wenche, et al. Molecular genetics & genomic medicine 2016 3 (2) 223-31 - Different risk factors for advanced colorectal neoplasm in young adults.
Kim Ji Yeon et al. World journal of gastroenterology 2016 Apr 22(13) 3611-20 - A novel quantitative method of pten expression assessment in tumor tissue.
Waniczek D, et al. Journal of biological regulators and homeostatic agents 0 0 (1) 79-90 - Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response.
Li Zhe-Zhen, et al. Oncotarget 2016 4 - PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies.
Paleari L et al. Clinical oncology (Royal College of Radiologists (Great Britain)) 2016 May (5) 317-26 - Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement
K Bibbins-Domingo et al, Ann Int Medicine, April 2016 - Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force
SP Dehmer et al. Ann Internal Medicine, April 2016 - Distribution of KRAS and BRAF Mutations in Metastatic Colorectal Cancers in Turkish Patients.
Gorukmez Orhan, et al. Asian Pacific journal of cancer prevention : APJCP 2016 0 (3) 1175-9 - KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients.
Olmedillas López Susana, et al. International journal of molecular sciences 2016 0 (4) - Nanofluidic digital PCR and extended genotyping of RAS and BRAF for improved selection of metastatic colorectal cancer patients to anti-EGFR therapies.
Azuara Daniel, et al. Molecular cancer therapeutics 2016 4 - The Prognostic Influence of BRAF Mutation and other Molecular, Clinical and Laboratory Parameters in Stage IV Colorectal Cancer.
Karadima Maria L, et al. Pathology oncology research : POR 2016 3 - BRAF mutation may have different prognostic implications in early- and late-stage colorectal cancer.
Chen Kuo-Hsing, et al. Medical oncology (Northwood, London, England) 2016 5 (5) 39 - Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance.
Temraz Sally, et al. Critical reviews in oncology/hematology 2016 3
- Human (0)
- Pathogen (5)
- Human (3918)
- Pathogen (0)
- Human (200)
- Pathogen (0)
No hay comentarios:
Publicar un comentario